A PHASE 4, MULTINATIONAL, MULTICENTRE, DOUBLE BLIND, DOUBLE DUMMY, RANDOMIZED, PARALLEL GROUP, CONTROLLED CLINICAL STUDY OF FIXED COMBINATION BECLOMETHASONE DIPROPIONATE 100 µg PLUS FORMOTEROL FUMARATE 6 µg pMDI WITH HFA-134A PROPELLANT (CHF1535, FOSTER) VERSUS FLUTICASONE 250 µg PLUS SALMETEROL 50 µg DPI (SERETIDE DISKUS) AS MAINTENANCE TREATMENT IN CONTROLLED ASTHMATIC PATIENTS.

Trial Profile

A PHASE 4, MULTINATIONAL, MULTICENTRE, DOUBLE BLIND, DOUBLE DUMMY, RANDOMIZED, PARALLEL GROUP, CONTROLLED CLINICAL STUDY OF FIXED COMBINATION BECLOMETHASONE DIPROPIONATE 100 µg PLUS FORMOTEROL FUMARATE 6 µg pMDI WITH HFA-134A PROPELLANT (CHF1535, FOSTER) VERSUS FLUTICASONE 250 µg PLUS SALMETEROL 50 µg DPI (SERETIDE DISKUS) AS MAINTENANCE TREATMENT IN CONTROLLED ASTHMATIC PATIENTS.

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs Beclometasone/formoterol; Salmeterol/fluticasone propionate
  • Indications Asthma
  • Focus Therapeutic Use
  • Acronyms FACTO
  • Sponsors Chiesi Farmaceutici
  • Most Recent Events

    • 20 Apr 2012 Additional locations (France, Netherlands, Spain) added as reported by ClinicalTrials.gov.
    • 28 Sep 2011 Status changed from active, no longer recruiting to completed.
    • 28 Sep 2011 Results presented at the 21st Annual Congress of the European Respiratory Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top